OraSure (OSUR) Q2 2026 earnings review
Core Revenue Stabilizes, But Flagship Catalyst is Pulled
OraSure delivered $30.6M in Q2 revenue, up 10% sequentially and flat YoY, indicating its core Diagnostics and Sample Management segments are finally stabilizing. Gross margins improved to 44.2% (Non-GAAP) thanks to internal manufacturing efficiencies. However, a massive red flag emerged: the company withdrew its FDA submission for the InteliQuick CT/NG test. Over the last four quarters, management relentlessly pitched this test as the primary driver for a massive H2 2026 growth ramp. The withdrawal severely damages the near-term growth narrative. Furthermore, the reported GAAP operating income of $5.4M is an accounting illusion; it was entirely driven by a $22.6M reversal of contingent consideration liabilities directly tied to the delayed CT/NG milestones. Underlying Non-GAAP operating loss actually worsened YoY to $14.7M.
🐂 Bull Case
The company secured FDA clearance for its Colli-Pee Dx at-home urine collection kit for use with Roche's STI tests, validating its decentralization strategy and opening a new commercial pathway.
Non-GAAP gross margin expanded to 44.2% (from 43.2% a year ago), proving that the painful transition of manufacturing to in-house Pennsylvania facilities is yielding structural profitability improvements.
🐻 Bear Case
The withdrawal of the InteliQuick CT/NG FDA submission removes the company's largest stated growth catalyst for 2026, pushing out expected revenue and threatening the timeline for cash flow breakeven.
Despite top-line stabilization, Non-GAAP operating loss widened to $14.7M (from $13.2M a year ago). The company has burned ~$38M in cash over the last six months.
⚖️ Verdict: 🔴
Bearish. While top-line stabilization and the Colli-Pee clearance are positive, withdrawing the CT/NG submission breaks the core investment thesis management built over the past year. The GAAP profitability is a mirage masking persistent core operating losses.
Key Themes
InteliQuick CT/NG Delay Contradicts Growth Narrative
Management withdrew the FDA submission for the InteliQuick CT/NG self-test (on the Sherlock platform) to 'incorporate feedback.' For the past four quarters, management repeatedly highlighted this product—targeting a >$1.5B market—as the primary catalyst for a return to growth in H2 2026. This delay not only pushes out critical revenue but also triggered a massive $22.6M reduction in contingent consideration liability. Management essentially reduced the probability or delayed the timeline of paying out acquisition milestones, generating a non-cash gain that artificially inflated Q2 GAAP operating income to $5.4M.
Colli-Pee FDA Clearance Validates Strategy
A major technological innovation milestone was achieved with the FDA clearance of the Colli-Pee Dx urine collection kit for use with Roche's STI tests (CT, NG, TV, MG). This allows for at-home, first-void urine self-collection. It directly supports the company's 'decentralized diagnostics' strategy and provides a tangible product to drive Sample Management growth to offset the delayed Sherlock platform.
Insourcing Drives Structural Margin Expansion
Non-GAAP gross margin improved to 44.2% from 43.2% in Q2 2025. This accelerating trend validates the strategy of consolidating third-party manufacturing into the company's Pennsylvania facilities. Because the plant is still operating well below full capacity, future volume stabilization provides a runway for significant operating leverage.
Cash Burn and Profitability Timeline Under Threat
Management previously guided to reaching breakeven operating cash flow by early 2027. However, operating cash flow for the first half of 2026 was negative $23.8M, and Non-GAAP operating loss widened YoY to $14.7M in Q2. With the primary revenue catalyst (CT/NG) now delayed indefinitely, the company will likely need to cut operational costs significantly to defend its $160.5M cash pile and hit its 2027 breakeven target.
Macro Uncertainty in Public Health and NIH Funding
While Core revenues stabilized, the broader macro environment remains a headwind. Previous quarters highlighted sluggish NIH grant funding and unpredictable public health budgets. Sample Management revenues remained flat YoY at $9.9M, indicating that academic and government customer demand has not yet re-accelerated to historical norms.
Ebola 2.0 Emergency Use Authorization
The FDA granted Emergency Use Authorization for the OraQuick Ebola 2.0 Rapid Antigen Test for use with whole blood and cadaveric oral fluid. While not expected to be a massive commercial driver, it entrenches OraSure's relationship with global public health agencies and demonstrates the utility of its rapid test formats for emerging infectious diseases.
Other KPIs
Stable YoY, but accelerating sequentially (+10% vs Q1 2026). Diagnostics contributed $19.4M (+1% YoY) and Sample Management Solutions contributed $9.9M (flat YoY). This halts the multi-quarter trend of YoY revenue contraction and suggests the baseline business has found a floor.
Reversing downward. Worsened compared to a loss of $13.2M in Q2 2025. While gross margins improved, elevated operating expenses continue to drag on profitability. Investors must look past the GAAP operating income of $5.4M, which was artificially created by a one-time $22.6M adjustment to contingent liabilities.
Down from $199.3M at the end of 2025. The company burned through roughly $38.7M in the first half of 2026 (including $7M deployed for share repurchases). While the balance sheet remains debt-free, the accelerating cash burn rate requires close monitoring given the delay in new product launches.
Guidance
Accelerating YoY. The midpoint of $31.0M represents an implied 14% YoY increase compared to Q3 2025 ($27.1M). Sequentially, it implies a flat to slightly higher performance versus Q2 2026, confirming that the destocking and funding headwinds that plagued 2025 are largely in the rearview mirror.
Key Questions
CT/NG Submission Feedback
What specific feedback from the FDA necessitated the withdrawal of the InteliQuick CT/NG submission, and what is the realistic timeline for a new submission and subsequent commercial launch?
Contingent Liability Reversal
The $22.6M reduction in contingent consideration suggests a material change in management's internal probability of hitting the Sherlock platform milestones. Does this reflect purely a timing delay, or a structural change in the market opportunity assessment?
Protecting the 2027 Breakeven Target
With the CT/NG revenue ramp delayed, is the target to achieve breakeven operating cash flow by early 2027 still viable? If so, what magnitude of OpEx reductions will be required to offset the missing revenue?
Colli-Pee Commercial Rollout
Now that Colli-Pee has secured FDA clearance for use with Roche's STI tests, what is the expected revenue cadence for this specific partnership in the second half of 2026?